Research work · 2012

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

George D. Demetri, Peter Reichardt, Yoon‐Koo Kang, Jean‐Yves Blay, Piotr Lukasz Rutkowski, Hans A. J. Gelderblom, Peter Hohenberger, Michael Gordon Leahy, Margaret von Mehren, Heikki Joensuu, Giuseppe Badalamenti, Martin E. Blackstein, Axel Le Cesne, Patrick Schöffski, Robert G. Maki, Sebastian Bauer, Binh Bui Nguyen, Jianming Xu, Toshirou Nishida, John Chung

The Lancet

Download PDF

DOI: 10.1016/s0140-6736(12)61857-1